BofA Securities analyst Michael Ryskin maintains $IQVIA Holdings (IQV.US)$ with a buy rating, and maintains the target price at $255.
According to TipRanks data, the analyst has a success rate of 40.9% and a total average return of -1.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $IQVIA Holdings (IQV.US)$'s main analysts recently are as follows:
The market is assessed as relatively stable, yet the challenges in bookings are primarily due to delays and drug failures rather than a significant impact from pipeline rationalization.
The company has encountered a challenging industry operating environment. However, indications suggest that pharmaceutical portfolio reprioritizations related to the IRA may be concluding, and the company seems to be gaining from the pharmaceutical industry's vendor consolidation trend.
The company surpassed consensus expectations with its total revenue, adjusted EBITDA, and adjusted EPS. Nonetheless, the company has reduced its 2024 guidance across all metrics. This revision is attributed to the effects of the Inflation Reduction Act and broader economic challenges. Additionally, R&DS guidance was lowered following delays and the cancellation of two 'mega' trials.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Michael Ryskin維持$艾昆緯 (IQV.US)$買入評級，維持目標價255美元。
根據TipRanks數據顯示，該分析師近一年總勝率為40.9%，總平均回報率為-1.1%。
此外，綜合報道，$艾昆緯 (IQV.US)$近期主要分析師觀點如下：
市場被評估爲相對穩定，然而預訂方面的挑戰主要是由於延遲和藥物失敗而非來自管道合理化的顯著影響。
公司遇到了具有挑戰性的行業經營環境。然而，跡象表明，與IRA相關的藥品組合重新排序可能即將結束，公司似乎從藥品行業的供應商整合趨勢中獲益。
公司的總收入、調整後的EBITDA和調整後的每股收益超出共識預期。然而，該公司已經在所有指標上降低了其2024年的指引。這一修訂歸因於通脹減輕法案的影響和更廣泛的經濟挑戰。此外，由於延遲和取消兩項「大型」試驗，研發指引也有所降低。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
